Loading
A phase 2/3 trial of Pertuzumab in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 2/3 interventional study registered as NCT07294508 by Shanghai Henlius Biotech, with 706 participants planned, started 2026-02-27 and due to reach its primary completion in 2028-01-15. Interventions recorded: HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab and THP.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/